Tags

Type your tag names separated by a space and hit enter

One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study.
Aliment Pharmacol Ther 2001; 15(12):1975-9AP

Abstract

BACKGROUND

The metronidazole resistance of Helicobacter pylori strains has increased rapidly.

AIM

To evaluate the efficacy and safety of new 1-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline.

METHODS

One hundred and twenty patients with H. pylori-positive inactive duodenal ulcer or non-ulcer dyspepsia diagnosed by endoscopy were recruited randomly to receive one of two regimens for 7 days: ranitidine bismuth citrate, 350 mg b.d., furazolidone, 100 mg b.d., and either amoxicillin, 1000 mg b.d. (n=60), or tetracycline, 500 mg b.d. (n=60). H. pylori infection was identified by rapid urease testing and histology. 13C-Urea breath test was performed to evaluate the cure of H. pylori infection at least 4 weeks after completion of triple therapy.

RESULTS

The eradication rates of H. pylori by ranitidine bismuth citrate-furazolidone-amoxicillin and ranitidine bismuth citrate-furazolidone-tetracycline regimens were 82% and 85% (P > 0.05), respectively, by intention-to-treat analysis, and 85% and 91% (P > 0.05), respectively, by per protocol analysis. Adverse effects were mild in both ranitidine bismuth citrate-furazolidone-amoxicillin and ranitidine bismuth citrate-furazolidone-tetracycline groups.

CONCLUSIONS

One-week regimens containing ranitidine bismuth citrate, furazolidone and amoxicillin or tetracycline are well tolerated and effective for the eradication of H. pylori.

Authors+Show Affiliations

Shanghai Institute of Digestive Disease, Shanghai Second Medical University, Shanghai, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11736729

Citation

Lu, H, et al. "One-week Regimens Containing Ranitidine Bismuth Citrate, Furazolidone and Either Amoxicillin or Tetracycline Effectively Eradicate Helicobacter Pylori: a Multicentre, Randomized, Double-blind Study." Alimentary Pharmacology & Therapeutics, vol. 15, no. 12, 2001, pp. 1975-9.
Lu H, Zhang DZ, Hu PJ, et al. One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study. Aliment Pharmacol Ther. 2001;15(12):1975-9.
Lu, H., Zhang, D. Z., Hu, P. J., Li, Z. S., Lu, X. H., Fang, X. C., & Xiao, S. D. (2001). One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study. Alimentary Pharmacology & Therapeutics, 15(12), pp. 1975-9.
Lu H, et al. One-week Regimens Containing Ranitidine Bismuth Citrate, Furazolidone and Either Amoxicillin or Tetracycline Effectively Eradicate Helicobacter Pylori: a Multicentre, Randomized, Double-blind Study. Aliment Pharmacol Ther. 2001;15(12):1975-9. PubMed PMID: 11736729.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study. AU - Lu,H, AU - Zhang,D Z, AU - Hu,P J, AU - Li,Z S, AU - Lu,X H, AU - Fang,X C, AU - Xiao,S D, PY - 2001/12/12/pubmed PY - 2002/4/16/medline PY - 2001/12/12/entrez SP - 1975 EP - 9 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 15 IS - 12 N2 - BACKGROUND: The metronidazole resistance of Helicobacter pylori strains has increased rapidly. AIM: To evaluate the efficacy and safety of new 1-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline. METHODS: One hundred and twenty patients with H. pylori-positive inactive duodenal ulcer or non-ulcer dyspepsia diagnosed by endoscopy were recruited randomly to receive one of two regimens for 7 days: ranitidine bismuth citrate, 350 mg b.d., furazolidone, 100 mg b.d., and either amoxicillin, 1000 mg b.d. (n=60), or tetracycline, 500 mg b.d. (n=60). H. pylori infection was identified by rapid urease testing and histology. 13C-Urea breath test was performed to evaluate the cure of H. pylori infection at least 4 weeks after completion of triple therapy. RESULTS: The eradication rates of H. pylori by ranitidine bismuth citrate-furazolidone-amoxicillin and ranitidine bismuth citrate-furazolidone-tetracycline regimens were 82% and 85% (P > 0.05), respectively, by intention-to-treat analysis, and 85% and 91% (P > 0.05), respectively, by per protocol analysis. Adverse effects were mild in both ranitidine bismuth citrate-furazolidone-amoxicillin and ranitidine bismuth citrate-furazolidone-tetracycline groups. CONCLUSIONS: One-week regimens containing ranitidine bismuth citrate, furazolidone and amoxicillin or tetracycline are well tolerated and effective for the eradication of H. pylori. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/11736729/One_week_regimens_containing_ranitidine_bismuth_citrate_furazolidone_and_either_amoxicillin_or_tetracycline_effectively_eradicate_Helicobacter_pylori:_a_multicentre_randomized_double_blind_study_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0269-2813&date=2001&volume=15&issue=12&spage=1975 DB - PRIME DP - Unbound Medicine ER -